ONASEMNOGENE ABEPARVOVEC
Information current as at: 1 July 2024
PBAC meeting date: November 2020
Submission Details
- Brand name:
-
- Zolgensma®
- Pharmaceutical company:
- Novartis Pharmaceuticals Australia Pty Limited
- Condition/indication:
(therapeutic use) -
- Spinal muscular atrophy (SMA)
- PBAC Submission type:
- New listing (Major submission)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – November 2020
- Related medicines:
Progress Details
-
Submission received for: - November 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 26/08/2020 and close 07/10/2020 (see PBS Website)
-
PBAC meeting: - Held on 04/11/2020
-
PBAC outcome published: - Deferred (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a258
Page last updated: 02 May 2024